Martinec Ondrej, Biel Carin, de Graaf Inge A M, Huliciak Martin, de Jong Koert P, Staud Frantisek, Cecka Filip, Olinga Peter, Vokral Ivan, Cerveny Lukas
Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia.
Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia.
Front Pharmacol. 2021 Jun 9;12:684156. doi: 10.3389/fphar.2021.684156. eCollection 2021.
P-glycoprotein (ABCB1), an ATP-binding cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug-drug interactions. Drug-mediated induction of intestinal ABCB1 is a clinically relevant phenomenon associated with significantly decreased drug bioavailability. Currently, there are no well-established human models for evaluating its induction, so drug regulatory authorities provide no recommendations for / testing drugs' ABCB1-inducing activity. Human precision-cut intestinal slices (hPCISs) contain cells in their natural environment and express physiological levels of nuclear factors required for ABCB1 induction. We found that hPCISs incubated in William's Medium E for 48 h maintained intact morphology, ATP content, and ABCB1 efflux activity. Here, we asked whether rifampicin (a model ligand of pregnane X receptor, PXR), at 30 μM, induces functional expression of in hPCISs over 24- and 48-h incubation (the time to allow complete induction to occur). Rifampicin significantly increased gene expression, protein levels, and efflux activity of ABCB1. Moreover, we described dynamic changes in ABCB1 transcript levels in hPCISs over 48 h incubation. We also observed that peaks of induction are achieved among donors at different times, and the extent of gene induction is proportional to PXR mRNA levels in the intestine. In conclusion, we showed that hPCISs incubated in conditions comparable to those used for inhibition studies can be used to evaluate drugs' ABCB1-inducing potency in the human intestine. Thus, hPCISs may be valuable experimental tools that can be prospectively used in complex experimental evaluation of drug-drug interactions.
P-糖蛋白(ABCB1)是一种ATP结合盒式外排转运蛋白,可限制其底物的肠道吸收,是药物相互作用的常见部位。药物介导的肠道ABCB1诱导是一种与药物生物利用度显著降低相关的临床相关现象。目前,尚无成熟的用于评估其诱导作用的人体模型,因此药物监管机构未提供评估药物ABCB1诱导活性的建议。人精密切割肠片(hPCIS)中的细胞处于自然环境中,并表达ABCB1诱导所需的生理水平的核因子。我们发现,在威廉姆斯E培养基中孵育48小时的hPCIS保持了完整的形态、ATP含量和ABCB1外排活性。在此,我们研究了30μM的利福平(孕烷X受体PXR的模型配体)在24小时和48小时孵育(允许完全诱导发生的时间)内是否能诱导hPCIS中ABCB1的功能性表达。利福平显著增加了ABCB1的基因表达、蛋白质水平和外排活性。此外,我们描述了hPCIS在48小时孵育过程中ABCB1转录水平的动态变化。我们还观察到,不同供体在不同时间达到诱导峰值,ABCB1基因诱导程度与肠道中PXR mRNA水平成正比。总之,我们表明,在与抑制研究相同的条件下孵育的hPCIS可用于评估药物在人肠道中的ABCB1诱导潜力。因此,hPCIS可能是有价值的实验工具,可前瞻性地用于药物相互作用的复杂实验评估。